Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.
Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.